Human CD38 Monoclonal Antibody

Catalog No.: YR0007



Basic Information

Molecular Weight

150 kDa

Endotoxin

<1EU/mg (<0.001EU/ μ g)Determined by LAL gel clotting assay

Sterility

0.2 µm filtration

Aggregation

<5% Determined by SECP

Purity

>95% Determined by SEC-HPLC

Background

Daratumumab Biosimilar uses the same protein sequences as the therapeutic antibody daratumumab. Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody. Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.

Reported Applications

ELISA,neutralization,functional assays such as bioanalytical P K and ADA assays,and those assays for studying biological pathways

Immunogen Information

Clone

Isotype

Daratumumab Biosimilar

human IgG1 kappa

Immunogen

Human CD38

RecommendedIsotype Control(s)

In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody

Recommended Dilution Buffer

1×PBS pH 7.0

Contact

<u>a</u>		400-999-6126
\bowtie	Τ	cn.market@abclonal.com.cn
•	ī	www.abclonal.com.cn

Product Information

Production

Purification

Purified from cell culture supernatant in an animal-free facility

Protein A or G purification

Storage

 $2 - 8^{\circ}$ C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)